Arcutis Biotherapeutics Inc (ARQT) Dividend History

$9.59 $0.32

Dividend Score
Dividend Yield
0%

Annual Payment
$0

Payout Ratio
0%
Dividend Increases
0 yrs

Price Chart

Key Metrics

Sector Healthcare
Industry Biotechnology
Avg daily volume 4,933,629
Market cap 897,460,000
Beta 1.15
Trailing 12 Month EPS -3.78
Next Earnings Date
Ex-dividend date
P/E ratio -3.42

Company Description

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Dividend Payments

Forward Yield
0%
Forward Payment
$0

Trailing Yield
0%
Trailing Payment
$0

Last Increase
> 10 Years Ago
Last Cut
> 10 Years Ago

5 Year Average Yield
0%
Vs Current Yield
0%

5 Year Div Growth Rate
0%
Payment Frequency
-

Historical Dividend Payments